ClinicalTrials.gg
CompletedNCT00717262Updated Jan 16, 2009

Phase 1 Placebo Controlled Study of the Safety, Activity and Pharmacokinetics of HQK-1001 in Healthy Subjects

A Phase 1 interventional study of HQK-1001 and placebo in Healthy, sponsored by HemaQuest Pharmaceuticals Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-01-16.

Sponsored by HemaQuest Pharmaceuticals Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, activity and pharmacokinetics of a new investigational drug (HQK-1001) in healthy human volunteers. This study will also evaluate if there are differences in these parameters when HQK-1001 is administered in a fed versus a fasted state.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

HemaQuest Pharmaceuticals Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female
  • Between the ages of 18 and 45 years old
  • Able and willing to give
  • Able to comply with all study procedures
  • If female, must not be of or must agree to use one or more of the following forms of during screening and throughout the study: hormonal (i.e., oral, transdermal, implant or injection); double barrier (i.e., condom, diaphragm with spermicide); intrauterine device (IUD); vasectomized partner (6 months minimum); or abstinence
  • Male subjects must also agree to use one or more of the above forms of birth control for either themselves or their partner, as appropriate, throughout the course of the study
  • Not receiving medications within the 2 weeks before the first dose of study medication, except for multivitamins and contraception
  • Complete blood count (CBC) with white blood cell (WBC) count , hematocrit, reticulocyte count and count within normal range for the testing facility or not
  • Serum ferritin level > 50 ng/ml in Cohort 1
  • Serum ferritin level > 30 mg/ml in Cohorts 2, 3, 4 and 5
  • Serum chemistry values, coagulation tests and urinalysis values within the normal range for the testing facility or not clinically significant
  • Negative urine test for substances of abuse including marijuana, cocaine, opiates, and methadone

Exclusion criteria

Exclusion Criteria:

  • Prior participation in HQP 2007-001
  • abnormal vital signs
  • Blood donation within 2 months of study medication administration
  • Blood transfusion within 3 months of study medication administration
  • An acute febrile illness or upper respiratory tract illness within 72 hours prior to administration of study medication
  • Received another agent within 4 weeks before administration of study medication
  • Receiving any other investigational agent during this study
  • Any acute or chronic disease (e.g., history of or C or -1)
  • Heart disease including an abnormal , clinical significant, (ECG) or cardiac arrhythmia
  • History of neurological disease, such as a seizure disorder
  • Currently pregnant or breast feeding a child
  • A smoker in the past 12 months
  • (BMI) >33 kg/m2
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
41 participants (estimated)

Study arms

  • Experimental
    1

    HQK-1001

    Drug: HQK-1001

  • Placebo comparator
    2

    Drug: placebo

Interventions

  • DrugDimebutic acidStudies of Dimebutic acidDimebutic acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.

  • Drugplacebo

    Matching placebo capsules administered once a day, orally, for 14 days.

06

What researchers measure

Primary outcomes

  1. Safety as assessed by (1) adverse events, (2) laboratory values (3) vital signs (4) physical exam

    Time frame: 41 days

Secondary outcomes

  1. Pharmacokinetics assessed by plasma drug concentration levels

    Time frame: 15 days

  2. Pharmacodynamics assessed by red blood cell production and induction of fetal hemoglobin

    Time frame: 41 days

  3. Comparison of safety, PK and PD under fed versus fasting conditions

    Time frame: 41 days

  4. Comparison of safety and PK when oral iron is administered with HQK-1001.

    Time frame: 41 days

07

Study locations

1 site
  • Charles River Clinical Services Northwest
    Tacoma, Washington 98403, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Aug 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2008
First posted
Jul 17, 2008
Start
May 2008
Primary completionActual
Aug 2008
CompletionActual
Sep 2008
Last update
Jan 16, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00717262
Lead sponsor
HemaQuest Pharmaceuticals Inc.
First posted
Jul 17, 2008
Start date
May 2008
Primary completion
Aug 2008
Completion
Sep 2008
Last update
Jan 16, 2009

Study contacts

Robin Downey, MD
principal investigator · Charles River Clinical Services Northwest

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimebutic acid

Start the discussion